Seelos Therapeutics, Inc. announced it will collaborate with the Sean M. Healey & AMG Center for ALS in an Expanded Access Program (EAP) that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS. Under this EAP, Seelos plans to initially enroll 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS in parallel to its ongoing Phase II/III study on the HEALEY Platform.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.39 USD | +4.51% | -14.72% | -87.50% |
05-16 | Seelos Therapeutics, Inc. announced that it expects to receive $1.137029 million in funding | CI |
05-14 | Seelos Therapeutics to Implement Reverse Stock Split to Regain Bourse Compliance | MT |
1st Jan change | Capi. | |
---|---|---|
-87.50% | 3.62M | |
+9.83% | 115B | |
+10.80% | 105B | |
-10.84% | 22.71B | |
-1.43% | 21.83B | |
-10.58% | 18.18B | |
-41.92% | 16.52B | |
-15.11% | 16.01B | |
+6.62% | 14.14B | |
+17.53% | 10.71B |
- Stock Market
- Equities
- SEEL Stock
- News Seelos Therapeutics, Inc.
- Seelos Therapeutics, Inc. to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program